Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357505 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP1A2TDP1CHRNB2CHRNA3 | |
| SCHEMBL18081175 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP1A2TDP1CHRNB2CHRNA3 | |
| SCHEMBL14590483 | 0.80 | CHRNB2 (0.48) | SMN1; SMN2CYP1A2TDP1CHRNB2CHRNA3 | |
| SCHEMBL3324237 | 0.80 | TSHR (0.33) | SMN1; SMN2TSHRMAPTGAARECQL | |
| SCHEMBL31665062 | 0.80 | TSHR (0.33) | SMN1; SMN2TSHRMAPTGAARECQL | |
| SCHEMBL25154698 | 0.79 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL25154764 | 0.79 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL25154426 | 0.79 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL25154680 | 0.79 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL357504 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA3CHRNA4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4242207-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | Tyligand Bioscience (Shanghai) Limited (CN) | 2023-09-13 | — | — | EP | disclosed |
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022095960-A1 | KRAS INHIBITORS FOR TREATMENT OF CANCERS | 泰励生物科技（上海）有限公司 | 2022-05-12 | — | — | WO | disclosed |
| EP-3209665-B1 | SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20170355698-A1 | HETEROARYL SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| EP-2336132-B1 | MORPHOLINOPURINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2014-01-01 | — | — | EP | disclosed |
| US-8309546-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2336132-A1 | MORPHOLINOPURINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-7329652-B2 | Diaminotriazole compounds useful as protein kinase inhibitors | VERTEX PHARAMACEUTICALS INCORPORATED (US) | 2008-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355698-A1 | HETEROARYL SUBSTITUTED PYRROLOTRIAZINE AMINE COMPOUNDS AS PI3K INHIBITORS | PIK3R3, PIK3R5, PIK3R1 | SMN1; SMN2 4616/4885CYP1A2 1964/4885TDP1 1703/4885 |
| US-20120071476-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | SMN1; SMN2 2875/4885CYP1A2 3323/4885TDP1 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.